Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate

J Pediatr. 1986 Jul;109(1):144-9. doi: 10.1016/s0022-3476(86)80596-0.


Four boys with persistent pubertal gynecomastia were given intramuscular dihydrotestosterone heptanoate (DHT-hp) at 2 to 4-week intervals for 16 weeks. By the end of treatment, breast size in all four boys had decreased 67% to 78%. Initial plasma levels of gonadotropins, estradiol, testosterone, and dihydrotestosterone (DHT) were normal. Mean plasma DHT concentration rose with the injections of DHT-hp, and remained elevated throughout the treatment period. Estradiol, LH, FSH, and testosterone decreased during treatment, as did 24-hour urinary LH and FSH. No regrowth of breast tissue was observed 6 to 15 months after treatment, although hormone concentrations had returned to near pretreatment values by 2 months after the last injection. DHT-hp has potential to be an effective medical therapy for persistent pubertal gynecomastia.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Dihydrotestosterone / analogs & derivatives*
  • Dihydrotestosterone / blood
  • Dihydrotestosterone / therapeutic use
  • Estradiol / blood
  • Follicle Stimulating Hormone / blood
  • Gynecomastia / blood
  • Gynecomastia / drug therapy*
  • Humans
  • Luteinizing Hormone / blood
  • Male
  • Puberty*
  • Testosterone / blood


  • Dihydrotestosterone
  • dihydrotestosterone heptanoate
  • Testosterone
  • Estradiol
  • Luteinizing Hormone
  • Follicle Stimulating Hormone